From the dawn of Crispr in 2012, medical scientists have recognized the gene-editing tool’s potential to treat, or even cure, genetic diseases.

New data from Intellia Therapeutics is making their hopes more realistic than ever. The company’s Crispr therapy was able to significantly lower patients’ levels of a misfolded liver protein and keep them low for months.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.